Biotechnology Prague headquartered clinical-stage SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix, a Lonza company, to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs. 13 March 2025